Are PCSK9 Inhibitors Cost Effective? Max J. KormanKjetil RetterstølTorbjørn Wisløff Leading Article 18 May 2018 Pages: 1031 - 1041
A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values Stavros PetrouJoseph KwonJason Madan Practical Application 10 May 2018 Pages: 1043 - 1061
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Lesley UttleyIñigo BermejoMatt Stevenson Review Article 15 March 2018 Pages: 1063 - 1072
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal Xavier ArmoiryMartin ConnockAileen Clarke Review Article 26 March 2018 Pages: 1073 - 1081
Review of Economic Value Drivers of the Treatment of Overactive Bladder Sonya J. Snedecor Review Article 04 May 2018 Pages: 1083 - 1092
Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References? T. Joseph Mattingly IIJoseph F. LevyEleanor M. Perfetto Short Communication Open access 12 May 2018 Pages: 1093 - 1099
Smoking Cessation: A Comparison of Two Model Structures Becky PenningtonAlex FilbyMatthew Taylor Original Research Article 08 May 2018 Pages: 1101 - 1112
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan Verin LertjanyakunNathorn ChaiyakunaprukYuichi Imanaka Original Research Article 30 April 2018 Pages: 1113 - 1124
Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO) Hui ShaoVivian FonsecaLizheng Shi Original Research Article 03 May 2018 Pages: 1125 - 1134
